Publicacions en col·laboració amb investigadors/es de University of Michigan Medical School (4)

2024

  1. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Hematopoiesis under telomere attrition at the single-cell resolution

    Nature Communications, Vol. 12, Núm. 1